Motorola's Rudyard Istvan Joins Iconix's Board of Directors
MOUNTAIN VIEW, Calif., Sept. 20 /PRNewswire/ -- Iconix Pharmaceuticals, a
chemical genomics-based biotechnology company, today announced that
Rudyard L. Istvan has joined the Company's Board of Directors. Mr. Istvan's
participation comes as part of the recently announced partnership between
Iconix and Motorola (NYSE: MOT) to enable the development of Iconix's next
generation chemical genomics database system, called ChemExpress(TM).
Mr. Istvan brings to Iconix over twenty years of experience in new
business creation, strategic planning and financing, and is a pioneer in the
emerging convergence between the hi-technology and life sciences industries.
He is a Senior Vice President of Motorola, Inc. and General Manager of Future
Businesses. Mr. Istvan has worldwide responsibility for identifying and
developing new business platforms, venture capital investing and licensing
certain classes of technology to outside interests. He heads Motorola's life
sciences initiative, which includes Motorola's BioChip Systems Division, and
Clinical Microsensors, the newest of the new business platforms. Prior to
joining Motorola in 1991, Mr. Istvan was a Senior Vice President of Boston
Consulting Group. Mr. Istvan holds a B.A. summa cum laude in economics from
Harvard College, a J.D. cum laude from Harvard Law School, and a M.B.A. from
Harvard Business School where he was Baker Scholar. He is a member of the
Massachusetts Bar, holds six U.S. patents and is the author of several
publications. In addition to Iconix, Mr. Istvan sits on the boards of
directors for Global Medical Products, Inc., Tissue Informatics, Inc., First
International Digital Corp., and Hadley School for the Blind.
"Rud possesses a unique blend of scientific, business, operational and
deal-making expertise, and I am pleased to welcome him to our Board," said
Keith Bostian, Iconix's President and Chief Executive Officer. "I am certain
that he will make an important contribution in our efforts to develop and
launch the ChemExpress database system."
About Iconix
Iconix Pharmaceuticals, Inc., is a technology leader in the field of
chemical genomics. Iconix's integrated platform technologies allow
pharmaceutical and biotechnology researchers to rapidly advance novel proteins
and drug targets identified by genomic studies into small-molecule drug
discovery, diagnostic and other therapeutic programs. In addition to Motorola,
Iconix collaborates with other drug discovery and development companies,
including Metabolex, Inc. in the field of Type II diabetes, and
Microcide, Inc. (Nasdaq: MCDE), Iconix's parent company and a shareholder, in
the field of viral genomics. For more information, visit Iconix at
iconixpharm.com .
About Motorola
Motorola, Inc., is a global leader in providing integrated communications
solutions and embedded electronic solutions. Sales in 1999 were
$33.1 billion. For more information, visit Motorola at
motorola.com .
Motorola BioChip Systems was established in 1998 to develop products which
enable the delivery of better healthcare through the understanding and
practical application of genomics. The business unit is currently developing a
family of biochip products and services for research and diagnostic
applications. The products under development at Motorola BioChip Systems will
enable scientists and healthcare professionals to quickly and accurately
analyze the DNA, RNA and proteins in living cells and enable the delivery of
more individualized healthcare.
NOTE: Motorola and the Motorola logo are registered trademarks of
Motorola Inc.
SOURCE Iconix Pharmaceuticals, Inc.
Web Site: iconixpharm.com |
